Treatment's approval marks exciting new development for patients with ES-SCLC to prevent CIM.
Bryan Fitzgerald, PharmD, BCOP
Advertisement
Articles by Bryan Fitzgerald, PharmD, BCOP
Watch for alopecia, arthralgia, diarrhea, fatigue, nausea, pyrexia, rash, and vomiting, among others.
Tisotumab vedotin-tftv is used as antitumor therapy for patients with disease progression during or after chemotherapy.
Clinicians cite long-term complications and younger patients with better prognoses as reasons to pull back on oropharyngeal cancer therapy.
Addition of atezolizumab and durvalumab to chemotherapy is a win for patients with extensive-stage small cell lung cancer
Advertisement
Latest Updated Articles
Study: How Individual Carbohydrate Responses Reveal Metabolic Health and Potential BiomarkersPublished: June 12th 2025 | Updated: June 16th 2025
Department of Health and Human Services Reconstitutes ACIP, Removing 17 Sitting MembersPublished: June 10th 2025 | Updated: June 12th 2025
NLA 2025: Managing Omega-3 Therapy With Statins, PCSK9 Inhibitors for Cardiovascular CarePublished: June 2nd 2025 | Updated: June 11th 2025
ASCO 2025: Zongertinib Shows Strong Potential in HER2-Mutant NSCLC Treatment LandscapePublished: June 3rd 2025 | Updated: June 11th 2025
Emerging Data: Impacts of ROCKstar and AGAVE-201Published: May 30th 2025 | Updated: June 5th 2025
Measles Cases Climb to 800 in United States as Outbreak Spreads Across BordersPublished: April 18th 2025 | Updated: April 21st 2025
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
NCCN Guideline Update in SCLC Adds Maintenance Lurbinectedin, Removes Chemotherapy-Free Interval
2
IMS 2025: Improving Outcomes with Bispecifics in Multiple Myeloma
3
Infection Risk Management in Patients With Multiple Myeloma on T-Cell Engaging Therapies
4
Elranatamab Plus Daratumumab and Lenalidomide Yields Durable Responses, Manageable Safety
5
